ArticleJAMA network open2026
Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: In March 2020, the US Food and Drug Administration (FDA) issued a boxed warning for montelukast amid reports of neuropsychiatric adverse effects. Objective: To determine whether a boxed warning for montelukast was associated with changes in prescription rates of montelukast to treat asthma in the US. Design, Setting, and Participants: In this serial cross-sectional study using a national commercial insurance claims database, monthly cohorts of individuals aged 6 years and older with an asthma diagnosis and continuous insurance coverage in the past year were created from October 2017 to December 2022. Results were stratified by age group, inhaled corticosteroid (ICS) use, and 1 or more asthma-related emergency department visit or hospitalization in the prior year. Data were analyzed from August 2024 to June 2025. Exposures: Announcement of a boxed warning for montelukast in March 2020. Main Outcomes and Measures: Monthly incidence and prevalence of montelukast use among patients with asthma. Data were analyzed with an interrupted time series analysis using segmented ordinary least-squares linear regression models with Newey-West standard errors. Results: The number of patients with asthma ranged from 594 253 in October 2017 to 614 637 in December 2022. In October 2017, 348 359 patients (58.6%) were female, 113 913 (19.2%) were younger than age of 18 years, 292 730 (49.3%) used an ICS, and 105 869 (17.8%) had 1 or more asthma-related emergency department visit or hospitalization in the prior year. The baseline monthly prevalence of montelukast use was 160.0 per 1000 patients with asthma, and the baseline incidence of new montelukast use was 5.8 per 1000. After the boxed warning, the level of monthly incident montelukast prescriptions decreased by 1.7 (95% CI, -2.2 to -1.3) per 1000 and the trend in montelukast prevalence decreased by 0.9 (95% CI, -1.1 to -0.6) per 1000 per month relative to the prewarning trend. The trend in prevalent montelukast use decreased after the boxed warning across all age and asthma severity subgroups. Conclusions and relevance: In this cross-sectional study of commercially insured patients with asthma, an FDA boxed warning for montelukast was associated with changes in asthma treatment use among patients of all ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.